Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

SEATTLE, Jan. 9 /PRNewswire/ -- Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co- lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has three ongoing PharmacoSurgery clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-looking statements." These statements include, but are not limited to, those regarding Omeros' proposed initial public offering and expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros' clinical development activities, regulatory oversight, intellectual property rights and other risks. Omeros undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise. SOURCE Omeros Corporation


'/>"/>
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported today that ... total of 10,672,750 common share purchase warrants have been exercised ... the exercise of these warrants totalled $1,387,458 and 10,672,750 common ... ... expression of confidence by our warrant holders. This infusion of ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
Breaking Biology News(10 mins):